Bristol Myers Squibb Tops Q4 Estimates
Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.
Bristol-Myers Squibb (BMY) Gets a Hold from Citi
Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...